CUL5 and renal cell carcinoma: Our results indicate that, while VHL is disrupted in both PCC and RCC, other components of the VHL elongin BC complex, particularly RBX1 and CUL5, are significantly disrupted in PCC and their status might be an important clinical consideration in PCC.